Repligen acquires BioFlash

Repligen Corporation (Nasdaq: RGEN) announced today that it has acquired the assets of BioFlash Partners, LLC, (BioFlash) including a technology platform for the production of pre-packed, "plug and play" chromatography columns. This patented technology enables economical production of chromatography columns in a format that is ready for use in the production of a broad range of biopharmaceuticals including monoclonal antibodies, vaccines and recombinant proteins. The terms of the acquisition include an upfront payment of $1.8 million, a contingent milestone and royalties based on product sales. A product offering based on this technology is being launched this week at the IBC Biopharmaceutical Development and Production conference under the brand name Opus(TM). The global market for chromatography media used in the production of biopharmaceuticals is estimated to be approximately $500 million.

"We are very pleased to have acquired the BioFlash platform, a technology which will enable us to meet the growing market need for flexible, pre-packed chromatography products," stated Walter C. Herlihy, President and Chief Executive Officer of Repligen Corporation. "The acquisition and launch of the Opus(TM) products reflects Repligen's ongoing commitment to leveraging our core competency in bioprocessing into a broader purification product offering to the biopharmaceutical industry."

The Opus(TM) products are offered in a range of column diameters and bed heights and can be pre-packed with commercially available chromatography resins including immobilized Protein A. "Plug and play" chromatography columns have the potential to improve the speed of process development and reduce the cost of biopharmaceutical manufacturing by decreasing the time associated with set-up, cleaning and validation of traditional manufacturing technologies.

SOURCE Repligen Corporation